The Prospects for an IP Waiver Under the TRIPS Agreement
Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.
Timo Minssen
-
Read more: The Prospects for an IP Waiver Under the TRIPS Agreement -
Read more: TWIHL: Innovation and Protection: The Future of Medical Device Regulation, Episode 3 TWIHL: Innovation and Protection: The Future of Medical Device Regulation, Episode 3
This episode looks at the effects of the COVID-19 pandemic on medical device regulation in the U.S. and abroad.
-
Read more: Sweden’s Response to COVID-19: A Tale of Trust, Recommendations, and Odorous Nudges Sweden’s Response to COVID-19: A Tale of Trust, Recommendations, and Odorous Nudges
The trust-based Swedish approach to the Corona-crisis — relatively moderate compared to most other countries — has been both hailed and heavily criticized.
-
Read more: Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2) Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2)
By Marcelo Corrales Compagnucci, Janos Meszaros & Timo Minssen This post is the second part in a two-part series about nudge theory, health data, and the U.K.’s National Data Opt-out System. You can read the first part here. Governments are always actively trying to improve their health care systems, and the secondary use of health…
-
Read more: Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I) Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)
By Marcelo Corrales Compagnucci, Janos Meszaros & Timo Minssen Empirical studies in behavioral economics have demonstrated how people are biased and often make poor decisions against their best interests. This has led policy makers to promote choice-preserving approaches, a.k.a. nudges. However, there has also been an increasingly vocal group of legal scholars who are interest…
-
Read more: Is Data Sharing Caring Enough About Patient Privacy? Part II: Potential Impact on US Data Sharing Regulations Is Data Sharing Caring Enough About Patient Privacy? Part II: Potential Impact on US Data Sharing Regulations
A recent US lawsuit highlights crucial challenges at the interface of data utility, patient privacy & data misuse By Timo Minssen (CeBIL, UCPH), Sara Gerke & Carmel Shachar Earlier, we discussed the new suit filed against Google, the University of Chicago (UC), and UChicago Medicine, focusing on the disclosure of patient data from UC to…
-
Read more: Is Data Sharing Caring Enough About Patient Privacy? Part I: The Background Is Data Sharing Caring Enough About Patient Privacy? Part I: The Background
By Timo Minssen (CeBIL, UCPH), Sara Gerke & Carmel Shachar A recent US lawsuit highlights crucial challenges at the interface of data utility, patient privacy & data misuse The huge prospects of artificial intelligence and machine learning (ML), as well as the increasing trend toward public-private partnerships in biomedical innovation, stress the importance of an effective…
-
Read more: Opportunities and challenges for user-generated licensing models in gene-editing Opportunities and challenges for user-generated licensing models in gene-editing
By Timo Minssen, Esther van Zimmeren & Jakob Wested An earlier version of this contribution had been published in Life Science Intellectual Property Review (LSIPR). A voluntary pool or clearinghouse model may give rise to a robust commercial ecosystem for CRISPR and could include special provisions for royalty-free research use by academics. Hence, there may be a path through…
-
Read more: Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle? Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle?
By Jakob Wested, Timo Minssen & Esther van Zimmeren Another version of this contribution has been published in Life Science Intellectual Property Review (LSIPR). The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the European Patent Office (EPO). Ultimately, some of the issues might still be referred…
-
Read more: Innovation and the Firm: Vertical Integration in Patent-Intensive Industries – Seminar 9/8 at the University of Copenhagen Innovation and the Firm: Vertical Integration in Patent-Intensive Industries – Seminar 9/8 at the University of Copenhagen
Looking forward to hear Professor Peter Lee’s (UC Davis) talk on “Innovation and the Firm: Vertical Integration in Patent-Intensive Industries” at the University of Copenhagen on Friday, Friday, September 8th 2017 from 10:00 – 12:00. If you are interested to join, please register here. Abstract of Professor Lee’s talk: Recent scholarship has highlighted the prevalence of…